[Long-term treatment using prostaglandin E2 in congenital heart defects with the pulmonary circulation being supplied by a patent ductus arteriosus].
作者信息
Hruda J, Samánek M, First T, Vorísková M, Skovránek J
出版信息
Cesk Pediatr. 1985 May;40(5):257-62.
PMID:3860302
Abstract
摘要
相似文献
1
2
Prostaglandin treatment of newborns with ductal-dependent congenital heart disease.
Pediatr Ann. 1981 Apr;10(4):29-38.
3
Use of prostaglandins in cardiopulmonary diseases of the newborn.
Semin Perinatol. 1980 Apr;4(2):135-41.
4
[Prostaglandin treatment of ductus-dependent congenital heart defects].
Lakartidningen. 1984 Oct 3;81(40):3619-22.
5
[Skeletal side effects of treatment with prostaglandin E1].
Rofo. 1984 Oct;141(4):427-30. doi: 10.1055/s-2008-1053163.
6
Oral administration of prostaglandin E2 in the hypoplastic left heart syndrome.
Jpn Heart J. 1983 May;24(3):481-7. doi: 10.1536/ihj.24.481.
7
[Prostaglandin therapy in newborn infants with a Botalli duct-dependent circulation].
Tijdschr Kindergeneeskd. 1985 Feb;53(1):20-5.
8
[Treatment of ductus-dependent congenital heart diseases with prostaglandin E1].
Ugeskr Laeger. 1979 Jul 9;141(28):1915-6.
9
The ductus arteriosus: why and how to manipulate its patency.
J Fla Med Assoc. 1983 Sep;70(9):788-93.
10
[Prolonged prostaglandin E-1 therapy of newborn infants with congenital heart defects].
Orv Hetil. 1980 May 18;121(20):1197-9.
Zotero 插件